HULL DONOSI BILTEN MPN RESOURCH FOUNDATION-A ZA MJESEC LIPANJ 2021. – POGLEDAJTE PREDAVANJE DR. SRĐANA VERSTOVŠEKA

Conference Highlights
 
Two significant conferences for the oncology and hematology research communities took place this month and each featured important content on MPNs.
 
At the American Society of Clinical Oncology's (ASCO) 2021 Annual Meeting, the MPN research presented included updates on several significant clinical trials for MF, including SIMPLIFY-1 (Momelotinib, Sierra Oncology) and BOREAS (KRT-232, Kartos Therapeutics). BOREAS is a new phase 3 study designed to evaluate a first-in-class small molecule inhibitor of MDM2, called KRT-232, in MF patients who no longer benefit from treatment with a JAK inhibitor. A literature review on outcomes of allogeneic hematopoietic cell transplants for MF was also presented at ASCO 2021, as well as numerous abstracts on Selinexor—a drug currently in trials (XPORT-MF-035 and XPORT-MF-034for the treatment of MF.

 
The European Hematology Association (EHA) Annual Congress also took place and brought virtual participants together from across the globe to share their latest findings and innovations in the field. Notable MPN updates included:
 

 
 
How does transfusion independence impact survival outcomes with momelotinib in MF?
 

 
  • Dr. Srdan Verstovsek's presentation on the benefits of Pelabresib in combination with Ruxolitinib. The two together appear to show significant spleen and symptom improvement over Ruxolitinib, alone, in this patient population.  
Benefits of pelabresib with ruxolitinib for treatment naïve myelofibrosis
 

 
 
Phase III trial of ruxolitinib plus parsaclisib in treatment-naïve myelofibrosis
 
EHA 2021 also featured content on managing the toxicity of JAK2 inhibitors, as well as trial updates for Imetelstat (IMbark, IMerge; Geron) and Navitoclax (REFINE; AbbVie).
 
To learn more about the content that was shared at this month's conferences, be sure to check out our social media channels or visit the ASCO and EHA online libraries.

 
Community News & Events

 

 
Blood On the Trail
 
Avid hiker and PV patient, Gary Linehan, embarked on a 272-mile journey on June 22nd to build awareness about MPNs and raise funds for MPNRF. Be sure to follow Gary’s exciting 4-week adventure and join us in cheering him on each step of the way! You can read Gary’s story and show your support on his event page.

 

 
It's Not Too Late. Watch Today!
 
Patient Empowerment Network (PEN) hosted a webinar on June 1st, called How to Play an Active Role in Your MPN Treatment and Care Decisions. The goal of this event was to help MPN patients engage with their healthcare team to receive the best treatment for their condition. The event featured MPN expert Dr. Naveen Pemmaraju and can be viewed on-demand today.

 

 
Treasure Sale to Benefit MPN Research Foundation
 
In support of her son who has Essential Thrombocythemia (ET), Peggy Patrick has been working hard to organize a special Treasure Sale fundraiser, with all proceeds going to MPNRF. She’s been collecting donated items from the public and is now hosting weekly Treasure Sales in the storefront of a former shoe store in downtown Virginia, MN. Learn more about Peggy’s fundraising efforts in this recent article by the Mesabi Tribune.

 
Featured Clinical Trials

 

 
Trial Name: PACIFICA
Company: CTI Biopharma
 
Study: Phase 3 study evaluating Pacritinib compared to physician's choice therapy in patients with MF and severe thrombocytopenia. This study was designed to use the Pacritinib 200 mg twice daily oral dose.
 
EnrollingIntermediate- to high-risk MF patients who have had no or limited exposure to any JAK2 inhibitor and who have severe thrombocytopenia (platelet count <50,000/µL). Participants treated with more than one JAK2 inhibitor are ineligible.
 
To learn more click here.

 
Trial NameXPORT-MF-035
Company: Karyopharm Therapeutics Inc.
 
Study: Phase 2 study to evaluate Selinexor versus treatment of physician’s choice in participants with previously treated MF. Selinexor is orally administered and blocks the transport of several proteins involved in cancer-cell growth.
 
Enrolling: MF patients who have had at least 6 months of treatment with a JAK 1 or 2 inhibitor. Individuals who have had previous treatment with Selinexor or other exportin 1 (XPO1) inhibitors are ineligible.
 
 
To learn more click here.

 
Welcome to MPNRF!

 
We are happy to introduce two new members of the MPNRF team!
 
Kendra Waddington joined our team earlier this month as our new Director of Development. In this role, she will be working with individuals, families, foundations, and others to raise funds in support of MPN research and patients. She looks forward to connecting with the many members of our MPN community.
 
Stephanie Fisher joins us July 1 and will be leading patient advocacy and biopharma engagement initiatives at MPNRF. She brings a wealth of experience to the team after having worked in rare diseases and advocacy roles. We are excited to welcome Stephanie into this new chapter with MPNRF!

GIVE TO MPN RESEARCH
 
Our mission is supported by the generosity of our donors and sponsors.

 

 

 
180 N Michigan Avenue, Suite 1870 | Chicago, IL 60601